

Health Technology Assessment in Pharma: A Review of Major Decisions

<https://marketpublishers.com/r/HA40F3839FA5EN.html>

Date: April 2020

Pages: 82

Price: US\$ 2,750.00 (Single User License)

ID: HA40F3839FA5EN

Abstracts

REPORT SCOPE:

The current report provides details about HTA processes in countries such as U.S., Canada and U.K. This report highlights information and insights on the molecules which were recently approved in terms of regulatory and reimbursement decisions. The report includes policies, country-specific HTA activities, drug overviews, mechanisms of action, disease backgrounds, clinical evidence on safety and efficacy, regulatory scenarios, and HTA evaluation details.

REPORT INCLUDES:

45 tables

A detailed outlook on the HTA process and its approvals in major pharma industries

Insights into the recent HTA submissions to HTA agencies by top pharmaceutical manufacturers

Discussion on how HTA helps in the development of safe, and effective health policies, thereby benefitting both patient and health care providers

Information about the medical, social, economic and ethical issues related to the use of a health technology

Company profiles of market-leading players, including Janssen Pharmaceuticals

Inc., Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Co., and Hoffmann-La Roche Inc.

Contents

CHAPTER 1 INTRODUCTION

Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT

Introduction
Origins of Technology Assessment
Fundamental Concepts
Health Technology
Health Technology Categories
Purpose or Application
Stage of Diffusion
Health Technology Assessment
Purposes of HTA

CHAPTER 3 PHARMACEUTICAL INDUSTRY'S PERSPECTIVE ON HTA

HTA and Efficiency
HTA: A Cost Driver
Implementation Barriers

CHAPTER 4 OVERVIEW OF GLOBAL HTA ORGANIZATIONS

HTA in Europe
United Kingdom (England and Wales)
Scotland
Germany
France

Italy
HTA in North America
U.S.
Canada
HTA in the Asia-Pacific Region
Japan
China
Australia

CHAPTER 5 DARATUMUMAB (DARZALEX)

Overview of Daratumumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Multiple Myeloma: Disease Overview
Staging and Prognosis
Signs and Symptoms
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
Haute de sant? (HAS) France
CADTH (pCODR) Canada
Company Profile
JANSSEN PHARMACEUTICALS INC.

CHAPTER 6 TILDRAKIZUMAB (ILUMYA)

Overview of Tildrakizumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Psoriasis: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.

SMC Scotland
Company Profile
MERCK AND CO. INC.

CHAPTER 7 DURVALUMAB (IMFINZI)

Overview of Durvalumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Non-small Cell Lung Cancer: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH (pCODR) Canada
HAS France
Company Profile
ASTRAZENECA PLC

CHAPTER 8 ABEMACICLIB (VERZENIO)

Overview of Abemaciclib
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Breast Cancer: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH (pCODR) Canada
HAS France
Company Profile
ELI LILLY AND CO.

CHAPTER 9 OCRELIZUMAB (OCREVUS)

Overview of Ocrelizumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Multiple Sclerosis: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH Canada
HAS France
Company Profile
HOFFMANN-LA ROCHE INC.

CHAPTER 10 CONCLUSION

List Of Tables

LIST OF TABLES

Table 1: Types of Health Technologies, by Category
Table 2: Types of Health Technologies, by Application
Table 3: Types of Health Technologies, by Stage of Diffusion
Table 4: National Healthcare Spending in Germany, by Sector/ Services, 2015-2017
Table 5: Key Organizations Involved in the Reimbursement of Pharmaceuticals and Medical Devices in France
Table 6: Key Organizations Involved in the Reimbursement of Pharmaceuticals in the U.S.
Table 7: Public Health Insurance Programs in the U.S.
Table 8: National Healthcare Expenditures in Canada, 2010-2019
Table 9: National Healthcare Expenditures of Canada, by Sector/Service, 2017
Table 10: Trends in Japanese Healthcare Expenditures, 1995-2016
Table 11: National Healthcare Expenditures in Japan, by Sector/Service, 1995-2014
Table 12: Distribution Shares of Healthcare Spending on Pharmaceuticals in China, 2017
Table 13: Trends in the Number of Medicines Included in Previous National Essential Medicines Lists, 1982-2009
Table 14: National Health Expenditures in Australia, by Sector/Service, 2017-2018
Table 15: Key U.S. Clinical Trials on Daratumumab
Table 16: Multiple Myeloma International Staging System
Table 17: Regulatory Milestones of Daratumumab, 2013-2015
Table 18: NICE Technology Assessment of Daratumumab
Table 19: SMC Technology Assessment of Daratumumab
Table 20: HAS Technology Assessment of Daratumumab
Table 21: CADTH-pCODR Technology Assessment of Daratumumab
Table 22: Key U.S. Clinical Trials on Tildrakizumab
Table 23: Tildrakizumab Regulatory Milestones
Table 24: NICE Technology Assessment of Tildrakizumab
Table 25: SMC Technology Assessment of Tildrakizumab
Table 26: Key U.S. Clinical Trials on Tildrakizumab
Table 27: Regulatory Milestones of Durvalumab
Table 28: NICE Technology Assessment of Durvalumab
Table 29: SMC Technology Assessment of Durvalumab
Table 30: CADTH-pCODR Technology Assessment of Durvalumab
Table 31: HAS Technology Assessment of Durvalumab

Table 32: Key U.S. Clinical Trials on Abemaciclib

Table 33: Regulatory Milestones of Abemaciclib

Table 34: NICE Technology Assessment of Abemaciclib

Table 35: SMC Technology Assessment of Abemaciclib

Table 36: CADTH-pCODR Technology Assessment of Abemaciclib

Table 37: HAS Technology Assessment of Abemaciclib

Table 38: Key U.S. Clinical Trials on Ocrelizumab

Table 39: Incidence and Prevalence of Multiple Sclerosis Cases, by Country, 2016

Table 40: Regulatory Milestones of Ocrelizumab

Table 41: NICE Technology Assessment of Ocrelizumab

Table 42: SMC Technology Assessment of Ocrelizumab

Table 43: CADTH Technology Assessment of Ocrelizumab

Table 44: HAS Technology Assessment of Ocrelizumab

List Of Figures

LIST OF FIGURES

Figure 1: Shares of Healthcare Expenditures in the U.K., by Sector, 2017

Figure 2: IQWiG Technology Assessment Process

Figure 3: IQWiG Conclusions on the Benefits of Assessments

Figure 4: Shares of National Healthcare Expenditures in the U.S., by Sector, 2018

Figure 5: Schematic of the Reimbursement Process in the U.S.

Figure 6: Features of the Asia-Pacific Market

Figure 7: Shares of Drugs Listed in the National Formulary of China, by Therapeutic Area, 2017

Figure 8: Management of Advanced Non-small Cell Lung Cancer and Expected Outcomes

I would like to order

Product name: Health Technology Assessment in Pharma: A Review of Major Decisions

Product link: <https://marketpublishers.com/r/HA40F3839FA5EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA40F3839FA5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970